Clinical Advances in
Recent advancements have been made in the treatment of human epidermal growth factor receptor 2 (HER2)-positive cancers (breast cancer and gastrointestinal [GI] cancers). This has led to the development of new HER2 testing guidelines in breast cancer and new strategies are emerging for managing patients with low HER2 expression and those who are refractory to HER2-targeted therapies. HER3 overexpression has also been observed in various cancers and is currently being investigated as a therapeutic target. This curriculum discusses the new HER2 testing guidelines and explores the recent clinical advances and future prospects for HER2- and HER3-targeted therapy.
Supported by an independent educational grant from
Daiichi Sankyo
Trastuzumab duocarmazine in locally advanced and metastatic solid tumours and HER2-expressing breast cancer: a phase 1 dose-escalation and dose-expansion study.
Human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists clinical practice guideline focused update.
Safety, pharmacokinetics, and antitumour activity of trastuzumab deruxtecan (DS-8201), a HER2-targeting antibody-drug conjugate, in patients with advanced breast and gastric or gastro-oesophageal tumours: a phase 1 dose-escalation study.
Targeting HER2 in colorectal cancer: The landscape of amplification and short variant mutations in ERBB2 and ERBB3.
Steering Committee Chair
Professor
Breast Center
University of Munich
Munich, Germany
Professor/Chairman
Inserm Unit U981
Institut Gustave Roussy
Villejuif, France
Head
Breast Cancer Program
IOB Institute of Oncology
Madrid & Barcelona
Ruber International Hospital
Madrid, Spain
Professor, Head Division of Early Drug Development,
Istituto Europeo di Oncologia,
University of Milan
Milan, Italy
Associate Attending, Breast Medicine
Memorial Sloan Kettering Cancer Center
Associate Professor of Medicine
Weill Cornell Medical College
New York, New York
Chief
Department of Gastrointestinal Oncology
National Cancer Center Hospital East
Kashiwa, Japan